RxDoctor Payments DataLook up a doctor →

Steven Wolf, MD

Neurology · New York, NYNPI 1487645693

Payments from drug & device makers

$971,241in general payments, 2019–2025

Across 1,411 payments — averaging $688.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$217K
  • Neurelis, Inc.$134K
  • Takeda Pharmaceuticals U.S.A., Inc.$106K
  • Livanova USA, Inc.$96K
  • SK Life Science, Inc.$60K
  • Eisai Inc.$57K
  • plus $300K from 48 others
$107,388in research payments, 2019–2025

Across 85 payments — averaging $1263.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurelis, Inc.$60K
  • Neuropace, Inc.$48K

What the payments were for

  • Consulting fees$72,52617%
  • Speaking & faculty fees$299,71970%
  • Travel & lodging$24,7316%
  • Food & beverage$31,2287%
  • Education$350%
  • Gifts$600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB SA9$217,092
Neurelis, Inc.94$134,216
Takeda Pharmaceuticals U.S.A., Inc.29$106,344
Livanova USA, Inc.29$96,477
SK Life Science, Inc.124$60,228
Eisai Inc.99$57,363
UCB, Inc.188$52,874
Greenwich Biosciences, Inc.81$44,803
Jazz Pharmaceuticals Inc.103$42,278
Mallinckrodt Enterprises LLC22$24,321
Zogenix Inc.14$23,909
Immedica Pharma US, Inc.48$20,055
Sunovion Pharmaceuticals Inc.46$14,587
Supernus Pharmaceuticals, Inc.83$13,107
Mallinckrodt Hospital Products Inc.11$11,632
Aquestive Therapeutics, Inc.85$10,767
Otter Pharmaceuticals, LLC8$9,914
UCB Biosciences Inc.2$8,500
Monteris Medical Corporation22$8,301
Neuropace, Inc.38$7,029
Biomarin Pharmaceutical Inc.6$2,087
Lilly USA, LLC28$581
Otsuka America Pharmaceutical, Inc.24$479
Novartis12$461
Ironshore Pharmaceuticals Inc.22$389
Catalyst Pharmaceuticals, Inc.18$387
Tris Pharma Inc19$375
Biocodex, Inc.8$293
Nobelpharma America, LLC28$257
Sumitomo Pharma America, Inc.12$222
Sage Therapeutics, LLC11$208
Upsher-smith Laboratories LLC8$166
Aucta Pharmaceuticals, Inc.12$156
CSL Behring6$155
Adlon Therapeutics L.p.9$152
Aprecia Pharmaceuticals, LLC9$124
Teva Pharmaceuticals USA, Inc.5$101
Zimmer Biomet2$100
Pfizer4$85
AstraZeneca3$83
Neos Therapeutics, LP4$79
Impel Pharmaceuticals Inc.4$79
Biohaven Pharmaceutical Holding Company Ltd.4$70
AbbVie2$58
Azurity Pharmaceuticals, Inc.2$48
Springworks Therapeutics, Inc.2$41
Travere Therapeutics, Inc.4$38
Astellas Pharma US Inc1$37
Corium, LLC2$33
Neurocrine Biosciences, Inc.1$24
Luye Pharma (USA) Ltd.1$23
Johnson & Johnson1$23
Collegium Pharmaceutical, Inc.1$19
Medtronic1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$971,241 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$106,446
Medicare patients
247
Services billed
654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)47$307,830
IngrezzaValbenazine Tosylate16$194,181
AptiomEslicarbazepine Acetate56$94,684
BriviactBrivaracetam40$68,864
FycompaPerampanel34$46,829
NayzilamMidazolam33$40,639
VimpatLacosamide23$30,900
TrileptalOxcarbazepine17$29,779
Carbamazepine ErCarbamazepine149$26,140
Lacosamide183$24,366
Levetiracetam507$23,227
Divalproex Sodium295$23,072
KeppraLevetiracetam12$21,180
Keppra XrLevetiracetam12$20,199
ValtocoDiazepam14$17,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$24$194,18116 claims
UCB, Inc.Briviact, Nayzilam, Vimpat$52,874$140,40496 claims
Sunovion Pharmaceuticals Inc.Aptiom$14,587$94,68456 claims
Eisai Inc.Fycompa$57,363$46,82934 claims
UCB SAKeppra$217,092$21,18012 claims
Neurelis, Inc.Valtoco$134,216$17,36914 claims
Upsher-smith Laboratories LLCTopiramate$166$1,347130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →